JWH-015 je jedinjenje iz naftoilindolne familije koje deluje kao selektivni kanabinoidni agonist. Njegov afinitet za CB2 receptor je 13,8 nM, dok je njegov afinitet za CB1 383 nM, tako da se skoro 28 puta jače vezuje za CB2 nego CB1.[3] JWH-015 manifestuje slabu CB1 aktivnost, i nije selektivan u istoj meri kao JWH-133.[4] On ima imunomodulatorno dejstvo,[5][6] i CB2 agonisti potencijalno mogu da budu korisni u tretmanu bola i inflamacije.[7][8]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug and Alcohol Dependence 2000; 60:133-140.
↑Marriott KS, Huffman JW (2008). „Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor”. Current Topics in Medicinal Chemistry8 (3): 187–204. DOI:10.2174/156802608783498014. PMID18289088.
↑Ghosh S, Preet A, Groopman JE, Ganju RK (2006). „Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes”. Molecular immunology43 (14): 2169–79. DOI:10.1016/j.molimm.2006.01.005. PMID16503355.
↑Montecucco F, Burger F, Mach F, Steffens S (2008). „CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways”. American journal of physiology. Heart and circulatory physiology294 (3): H1145–55. DOI:10.1152/ajpheart.01328.2007. PMID18178718.